Indications and uses
Nystatin oral suspension is indicated for the treatment of candidiasis in the oral cavity.
Nystatin oral suspension is indicated for the treatment of candidiasis in the oral cavity.
INFANTS: 2 mL (200,000 units) four times daily (in infants and young children, use dropper to place one-half of dose in each side of mouth and avoid feeding for 5 to 10 minutes). NOTE: Limited clinical studies in premature and low birth weight infants indicate that 1 mL four times daily is effective. CHILDREN AND ADULTS: 4 to 6 mL (400,000 to 600,000 units) four times daily (one-half of dose in each side of mouth)...
Rx Only
Nystatin is an antimycotic polyene antibiotic obtained from Streptomyces noursei. Structural formula:
C 47H 75NO 17 MW 926.13
Nystatin Oral Suspension USP, for oral administration, contains 100,000 USP Nystatin Units per mL. Inactive ingredients: alcohol (≤ 1% v/v), artificial peppermint flavor, cherry flavor, citric acid, D&C Yellow No. 10, FD&C Red No. 40, glycerin, magnesium aluminum silicate, methylparaben, potassium phosphate dibasic, propylene glycol, propylparaben, purified water and sucrose.
Gastrointestinal absorption of nystatin is insignificant. Most orally administered nystatin is passed unchanged in the stool. In patients with renal insufficiency receiving oral therapy with conventional dosage forms, significant plasma concentrations of nystatin may occasionally occur.
Nystatin is both fungistatic and fungicidal in vitro against a wide variety of yeasts and yeast-like fungi. Candida albicans demonstrates no significant resistance to nystatin in vitro on repeated subculture in increasing levels of nystatin; other Candida species become quite resistant. Generally, resistance does not develop in vivo. Nystatin acts by binding to sterols in the cell membrane of susceptible Candida species with a resultant change in membrane permeability allowing leakage of intracellular components. Nystatin exhibits no appreciable activity against bacteria, protozoa, or viruses.
Nystatin oral suspension is indicated for the treatment of candidiasis in the oral cavity.
The preparation is contraindicated in patients with a history of hypersensitivity to any of its components.
This medication is not to be used for the treatment of systemic mycoses. Discontinue treatment if sensitization or irritation is reported during use.
No long-term animal studies have been performed to evaluate carcinogenic potential. There also have been no studies to determine mutagenicity or whether this medication affects fertility in males or females.
Animal reproduction studies have not been conducted with nystatin oral suspension. It is also not known whether nystatin oral suspension can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Nystatin oral suspension should be given to a pregnant woman only if clearly needed.
It is not known whether nystatin is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when nystatin is administered to a nursing woman.
Nystatin is well tolerated even with prolonged therapy. Oral irritation and sensitization have been reported. (See PRECAUTIONS: General).
Gastrointestinal: Diarrhea (including one case of bloody diarrhea), nausea, vomiting, gastrointestinal upset/disturbances.
Dermatologic: Rash, including urticaria has been reported rarely. Stevens-Johnson syndrome has been reported very rarely.
Other: Tachycardia, bronchospasm, facial swelling, and non-specific myalgia have also been rarely reported.
Oral doses of nystatin in excess of five million units daily have caused nausea and gastrointestinal upset. There have been no reports of serious toxic effects of superinfections (See CLINICAL PHARMACOLOGY, Pharmacokinetics).
INFANTS: 2 mL (200,000 units) four times daily (in infants and young children, use dropper to place one-half of dose in each side of mouth and avoid feeding for 5 to 10 minutes).
NOTE: Limited clinical studies in premature and low birth weight infants indicate that 1 mL four times daily is effective.
CHILDREN AND ADULTS: 4 to 6 mL (400,000 to 600,000 units) four times daily (one-half of dose in each side of mouth). The preparation should be retained in the mouth as long as possible before swallowing.
Continue treatment for at least 48 hours after perioral symptoms have disappeared and cultures demonstrate eradication of Candida albicans.
Nystatin Oral Suspension USP, 100,000 USP Nystatin Units per mL, is available in a cherry, peppermint flavored, light creamy yellow, ready-to-use suspension, supplied in the following oral dosage forms:
NDC 0121-0810-02: 2 fl oz (60mL) bottle with calibrated dropper
NDC 0121-0810-16: 16 fl oz (473mL) bottle
NDC 0121-4810-05: 5mL unit dose cup
NDC 0121-4810-40: Case contains 40 unit dose cups of 5mL (0121-4810-05) packaged in
4 trays of 10 unit dose cups each.
Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature]. Avoid freezing.
R10/16
Pharmaceutical Associates, Inc.
Greenville, SC 29605
www.paipharma.com
60 mL
NDC 0121-0810-02
Nystatin Oral Suspension, USP
100,000 units per mL
SHAKE WELL BEFORE USING
Packaged with Calibrated Dropper
DO NOT USE IF TAMPER EVIDENT
SEAL IS BROKEN OR MISSING.
Rx ONLY
Pharmaceutical Associates, Inc.
Greenville, SC 29605
Each mL of cherry, peppermint flavored
oral suspension contains 100,000 units
Nystatin, USP and alcohol (≤ 1% v/v).
USUAL DOSAGE: For Infants: 2 mL(200,000 units) four times daily (in infants andyoung children, use dropper to place one half of dose in each side of the mouth and avoid feeding feeding for 5 to 10 minutes). See insert.
WARNINGS: Keep this and all drugs out of reach of children. In case of accidental overdose, seek professional assistance orcontact a Poison Control Center immediately.
Keep tightly closed. Protect from light.
Store at 20° to 25°C (68° to 77°F)
[See USP Controlled Room Temperature}. AVOID FREEZING
R04/17
X01810020417
Delivers 5 mL
NDC 0121-4810-05
N
YSTATIN
O
RAL
S
USPENSION
, USP
500,000 units / 5 mL
Alcohol ≤ 1% v/v SHAKE WELL
Rx ONLY
FOR INSTITUTIONAL USE ONLY
PHARMACEUTICAL ASSOCIATES, INC.,
GREENVILLE, SC 29605
SEE INSERT
A48100500
| Class | Version | Type | Effective |
|---|---|---|---|
| NYSTATIN Pharmacologic Class Indexing | 2 | Indexing - Pharmacologic Class | 20180813 |
| Product concept | Relation | Version | Effective |
|---|---|---|---|
| e29fe634-dc25-094c-c77f-5d09c3eceb3e | Product name | 5 | 20260107 |
| 4b7700e3-6e0e-45e5-9d22-6f754d61386e | Product name | 2 | 20250304 |
| e57b6340-9387-3f9a-7307-511c81791375 | Product name | 3 | 20221214 |
| 544f8e8d-6389-eeeb-9586-aa447c08dcc7 | Product name | 5 | 20210614 |
| 1629e00f-54fb-4a43-8306-b58442b23902 | Product name | 9 | 20200430 |
| 854ec07b-1cd7-a5db-235a-7aa24d3cf97a | Product name | 3 | 20180628 |
| 19b9f4c1-15e9-edcc-4c16-f01ecfb5c549 | Product name | 1 | 20140508 |
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 0121-0810-02 | Nystatin | 60 mL in 1 BOTTLE, DROPPER | SUSPENSION | 60 | 9 | |
| 0121-0810-16 | Nystatin | 473 mL in 1 BOTTLE | SUSPENSION | 473 | 9 | |
| 0121-4810-00 | Nystatin | 10 in 1 TRAY | SUSPENSION | 10 | 9 | |
| 0121-4810-00 | Nystatin | 10 in 1 CASE | SUSPENSION | 10 | 9 | |
| 0121-4810-05 | Nystatin | 5 mL in 1 CUP, UNIT-DOSE | SUSPENSION | 5 | 9 | |
| 0121-4810-40 | Nystatin | 10 in 1 TRAY | SUSPENSION | 10 | 9 | |
| 0121-4810-40 | Nystatin | 4 in 1 CASE | SUSPENSION | 4 | 9 | |
| 0121-4810-50 | Nystatin | 5 in 1 CASE | SUSPENSION | 5 | 9 | |
| 0121-4810-50 | Nystatin | 10 in 1 PACKAGE | SUSPENSION | 10 | 9 |
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 0121-0810 | NYSTATIN SUSPENSION [PHARMACEUTICAL ASSOCIATES, INC.] | 9 | Current NDC, Legacy NDC, 2 package rows | 20220114_31e3da10-5a7b-4bc5-8a4f-3e786b64c13a.zip |
| 0121-4810 | NYSTATIN SUSPENSION [PHARMACEUTICAL ASSOCIATES, INC.] | 9 | Current NDC, Legacy NDC, 7 package rows | 20220114_31e3da10-5a7b-4bc5-8a4f-3e786b64c13a.zip |
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 0121-0810-02 | ML - Milliliter | 0121-0810 | 74585cc8-9e6f-4d89-9243-28d79ee1f4ee | 1 | 2016-09-02 |
| 0121-0810-16 | ML - Milliliter | 0121-0810 | 589842bf-fdae-4623-802f-571932da0a80 | 1 | 2016-09-02 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 0121-0810 | 0121-0810-02, 0121-0810-16 |
| 0121-4810 | 0121-4810-05, 0121-4810-40, 0121-4810-00, 0121-4810-50 |
Every source-derived ingredient row is available through these pages.
All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| A203621-001 | NYSTATIN | NYSTATIN | 100,000 UNITS/ML | SUSPENSION / ORAL | AA | 2016-01-07 |
| Application-product | TE code |
|---|---|
| A203621-001 | AA |
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-09-14 22:38:34 | 2026-08 | A203621-001 | NYSTATIN | 100,000 UNITS/ML | SUSPENSION / ORAL | AA | 2016-01-07 | 84e616aacf4f… | |
| 2026-08-18 06:07:40 | 2026-07 | A203621-001 | NYSTATIN | 100,000 UNITS/ML | SUSPENSION / ORAL | AA | 2016-01-07 | caaa826d4ba7… | |
| 2026-02-19 14:30 UTC | 2026-02 | A203621-001 | NYSTATIN | 100,000 UNITS/ML | SUSPENSION / ORAL | AA | 2016-01-07 | 011fe1cb6892… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A203621-001 | NYSTATIN | 100,000 UNITS/ML | SUSPENSION / ORAL | AA | 2016-01-07 | 31067a03dcf5… | |
| 2025-08-23 18:47 UTC | 2025-08 | A203621-001 | NYSTATIN | 100,000 UNITS/ML | SUSPENSION / ORAL | AA | 2016-01-07 | 6a471c1ec25d… | |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | A203621-001 | NYSTATIN | 100,000 UNITS/ML | SUSPENSION / ORAL | AA | 2016-01-07 | fd3edfee7708… | |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | A203621-001 | NYSTATIN | 100,000 UNITS/ML | SUSPENSION / ORAL | AA | 2016-01-07 | b8a1b40f171c… | |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | A203621-001 | NYSTATIN | 100,000 UNITS/ML | SUSPENSION / ORAL | AA | 2016-01-07 | 03ed91905a0d… | |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | A203621-001 | NYSTATIN | 100,000 UNITS/ML | SUSPENSION / ORAL | AA | 2016-01-07 | 2680178bc6a6… | |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | A203621-001 | NYSTATIN | 100,000 UNITS/ML | SUSPENSION / ORAL | AA | 2016-01-07 | 5bbf6a4d5a75… | |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | A203621-001 | NYSTATIN | 100,000 UNITS/ML | SUSPENSION / ORAL | AA | 2016-01-07 | d8e5a09893c0… | |
| 2024-10-29 15:01 UTC | 2024-10 | A203621-001 | NYSTATIN | 100,000 UNITS/ML | SUSPENSION / ORAL | AA | 2016-01-07 | d06236e962d9… | |
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | A203621-001 | NYSTATIN | 100,000 UNITS/ML | SUSPENSION / ORAL | AA | 2016-01-07 | 79d66fd596c7… | |
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | A203621-001 | NYSTATIN | 100,000 UNITS/ML | SUSPENSION / ORAL | AA | 2016-01-07 | 301d65b070ca… | |
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | A203621-001 | NYSTATIN | 100,000 UNITS/ML | SUSPENSION / ORAL | AA | 2016-01-07 | 1e350fbaab3a… | |
| 2024-05-31 18:47 UTC | 2024-05 | A203621-001 | NYSTATIN | 100,000 UNITS/ML | SUSPENSION / ORAL | AA | 2016-01-07 | 8072bd15b7f6… | |
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | A203621-001 | NYSTATIN | 100,000 UNITS/ML | SUSPENSION / ORAL | AA | 2016-01-07 | 5c6f7cd8ea54… | |
| 2022-04-08 23:34 UTC | 2022-04 | A203621-001 | NYSTATIN | 100,000 UNITS/ML | SUSPENSION / ORAL | AA | 2016-01-07 | 5d02ea3f76ae… | |
| 2022-04-04 05:41 UTC | 2022-04 | A203621-001 | NYSTATIN | 100,000 UNITS/ML | SUSPENSION / ORAL | AA | 2016-01-07 | 4b0b4de00fa7… | |
| 2019-12-13 00:20 UTC | 2019-12 | A203621-001 | NYSTATIN | 100,000 UNITS/ML | SUSPENSION / ORAL | AA | 2016-01-07 | 74a2ff9319b5… | |
| 2022-03-09 01:35 UTC | 2022-03 | A203621-001 | NYSTATIN | 100,000 UNITS/ML | SUSPENSION / ORAL | AA | 2016-01-07 | bb7c543d1eb4… | |
| 2021-12-28 21:50 UTC | 2021-12 | A203621-001 | NYSTATIN | 100,000 UNITS/ML | SUSPENSION / ORAL | AA | 2016-01-07 | 782e0a99824c… | |
| 2021-05-05 16:15 UTC · 3 captures of this ZIP | 2021-05 | A203621-001 | NYSTATIN | 100,000 UNITS/ML | SUSPENSION / ORAL | AA | 2016-01-07 | 87673890dc5c… | |
| 2021-03-12 10:30 UTC | 2021-03 | A203621-001 | NYSTATIN | 100,000 UNITS/ML | SUSPENSION / ORAL | AA | 2016-01-07 | 5aa47cf7b7d7… | |
| 2020-12-22 03:56 UTC | 2020-12 | A203621-001 | NYSTATIN | 100,000 UNITS/ML | SUSPENSION / ORAL | AA | 2016-01-07 | 8869cabd3fbd… | |
| 2020-11-12 02:37 UTC | 2020-11 | A203621-001 | NYSTATIN | 100,000 UNITS/ML | SUSPENSION / ORAL | AA | 2016-01-07 | c0c555d07b60… | |
| 2019-12-14 00:12 UTC | 2019-12 | A203621-001 | NYSTATIN | 100,000 UNITS/ML | SUSPENSION / ORAL | AA | 2016-01-07 | 3f01610625f2… | |
| 2019-09-15 20:21 UTC | 2019-09 | A203621-001 | NYSTATIN | 100,000 UNITS/ML | SUSPENSION / ORAL | AA | 2016-01-07 | b00525d2431f… | |
| 2019-07-19 19:46 UTC | 2019-07 | A203621-001 | NYSTATIN | 100,000 UNITS/ML | SUSPENSION / ORAL | AA | 2016-01-07 | ea99ee380514… | |
| 2024-03-16 18:09 UTC · 4 captures of this ZIP | 2024-03 | A203621-001 | NYSTATIN | 100,000 UNITS/ML | SUSPENSION / ORAL | AA | 2016-01-07 | 6a51e52b5d6a… | |
| 2024-02-18 07:12 UTC | 2024-02 | A203621-001 | NYSTATIN | 100,000 UNITS/ML | SUSPENSION / ORAL | AA | 2016-01-07 | 1c564ffb4f44… | |
| 2023-12-20 04:57 UTC | 2023-12 | A203621-001 | NYSTATIN | 100,000 UNITS/ML | SUSPENSION / ORAL | AA | 2016-01-07 | ea1830bbd6c7… | |
| 2023-11-28 05:40 UTC · 2 captures of this ZIP | 2023-11 | A203621-001 | NYSTATIN | 100,000 UNITS/ML | SUSPENSION / ORAL | AA | 2016-01-07 | a72a2bbeb626… | |
| 2023-10-25 00:34 UTC · 2 captures of this ZIP | 2023-10 | A203621-001 | NYSTATIN | 100,000 UNITS/ML | SUSPENSION / ORAL | AA | 2016-01-07 | 9b2671bbb829… | |
| 2023-07-15 15:27 UTC · 2 captures of this ZIP | 2023-07 | A203621-001 | NYSTATIN | 100,000 UNITS/ML | SUSPENSION / ORAL | AA | 2016-01-07 | a67488948f0b… | |
| 2023-06-13 01:57 UTC · 3 captures of this ZIP | 2023-06 | A203621-001 | NYSTATIN | 100,000 UNITS/ML | SUSPENSION / ORAL | AA | 2016-01-07 | 3f0d92c62455… | |
| 2023-05-13 08:27 UTC | 2023-05 | A203621-001 | NYSTATIN | 100,000 UNITS/ML | SUSPENSION / ORAL | AA | 2016-01-07 | 053a50430f4f… | |
| 2023-01-26 05:58 UTC | 2023-01 | A203621-001 | NYSTATIN | 100,000 UNITS/ML | SUSPENSION / ORAL | AA | 2016-01-07 | 3bdfa0b2c4d7… | |
| 2022-11-12 20:34 UTC · 5 captures of this ZIP | 2022-11 | A203621-001 | NYSTATIN | 100,000 UNITS/ML | SUSPENSION / ORAL | AA | 2016-01-07 | 3a93d1ddd44b… | |
| 2022-10-28 04:53 UTC | 2022-10 | A203621-001 | NYSTATIN | 100,000 UNITS/ML | SUSPENSION / ORAL | AA | 2016-01-07 | f41ea6bd6efb… |
| Captured | Edition | Application-product | TE code | Order | Source SHA-256 |
|---|---|---|---|---|---|
| 2026-09-14 22:38:34 | 2026-08 | A203621-001 | AA | 1 | 84e616aacf4f… |
| 2026-08-18 06:07:40 | 2026-07 | A203621-001 | AA | 1 | caaa826d4ba7… |
| 2026-02-19 14:30 UTC | 2026-02 | A203621-001 | AA | 1 | 011fe1cb6892… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A203621-001 | AA | 1 | 31067a03dcf5… |
| 2025-08-23 18:47 UTC | 2025-08 | A203621-001 | AA | 1 | 6a471c1ec25d… |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | A203621-001 | AA | 1 | fd3edfee7708… |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | A203621-001 | AA | 1 | b8a1b40f171c… |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | A203621-001 | AA | 1 | 03ed91905a0d… |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | A203621-001 | AA | 1 | 2680178bc6a6… |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | A203621-001 | AA | 1 | 5bbf6a4d5a75… |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | A203621-001 | AA | 1 | d8e5a09893c0… |
| 2024-10-29 15:01 UTC | 2024-10 | A203621-001 | AA | 1 | d06236e962d9… |
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | A203621-001 | AA | 1 | 79d66fd596c7… |
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | A203621-001 | AA | 1 | 301d65b070ca… |
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | A203621-001 | AA | 1 | 1e350fbaab3a… |
| 2024-05-31 18:47 UTC | 2024-05 | A203621-001 | AA | 1 | 8072bd15b7f6… |
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | A203621-001 | AA | 1 | 5c6f7cd8ea54… |
| 2022-04-08 23:34 UTC | 2022-04 | A203621-001 | AA | 1 | 5d02ea3f76ae… |
| 2022-04-04 05:41 UTC | 2022-04 | A203621-001 | AA | 1 | 4b0b4de00fa7… |
| 2019-12-13 00:20 UTC | 2019-12 | A203621-001 | AA | 1 | 74a2ff9319b5… |
| 2022-03-09 01:35 UTC | 2022-03 | A203621-001 | AA | 1 | bb7c543d1eb4… |
| 2021-12-28 21:50 UTC | 2021-12 | A203621-001 | AA | 1 | 782e0a99824c… |
| 2021-05-05 16:15 UTC · 3 captures of this ZIP | 2021-05 | A203621-001 | AA | 1 | 87673890dc5c… |
| 2021-03-12 10:30 UTC | 2021-03 | A203621-001 | AA | 1 | 5aa47cf7b7d7… |
| 2020-12-22 03:56 UTC | 2020-12 | A203621-001 | AA | 1 | 8869cabd3fbd… |
| 2020-11-12 02:37 UTC | 2020-11 | A203621-001 | AA | 1 | c0c555d07b60… |
| 2019-12-14 00:12 UTC | 2019-12 | A203621-001 | AA | 1 | 3f01610625f2… |
| 2019-09-15 20:21 UTC | 2019-09 | A203621-001 | AA | 1 | b00525d2431f… |
| 2019-07-19 19:46 UTC | 2019-07 | A203621-001 | AA | 1 | ea99ee380514… |
| 2024-03-16 18:09 UTC · 4 captures of this ZIP | 2024-03 | A203621-001 | AA | 1 | 6a51e52b5d6a… |
| 2024-02-18 07:12 UTC | 2024-02 | A203621-001 | AA | 1 | 1c564ffb4f44… |
| 2023-12-20 04:57 UTC | 2023-12 | A203621-001 | AA | 1 | ea1830bbd6c7… |
| 2023-11-28 05:40 UTC · 2 captures of this ZIP | 2023-11 | A203621-001 | AA | 1 | a72a2bbeb626… |
| 2023-10-25 00:34 UTC · 2 captures of this ZIP | 2023-10 | A203621-001 | AA | 1 | 9b2671bbb829… |
| 2023-07-15 15:27 UTC · 2 captures of this ZIP | 2023-07 | A203621-001 | AA | 1 | a67488948f0b… |
| 2023-06-13 01:57 UTC · 3 captures of this ZIP | 2023-06 | A203621-001 | AA | 1 | 3f0d92c62455… |
| 2023-05-13 08:27 UTC | 2023-05 | A203621-001 | AA | 1 | 053a50430f4f… |
| 2023-01-26 05:58 UTC | 2023-01 | A203621-001 | AA | 1 | 3bdfa0b2c4d7… |
| 2022-11-12 20:34 UTC · 5 captures of this ZIP | 2022-11 | A203621-001 | AA | 1 | 3a93d1ddd44b… |
| 2022-10-28 04:53 UTC | 2022-10 | A203621-001 | AA | 1 | f41ea6bd6efb… |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Nystatin | NYSTATIN | Pharmaceutical Associates, Inc. | 31e3da10-5a7b-4bc5-8a4f-3e786b64c13a | 2022-01-13 | Adverse reactions | 0121-4810-05 0121-4810-50 0121-0810-16 0121-0810-02 0121-4810-00 0121-4810-40 0121-0810 0121-4810 00121481005 00121081002 00121481000 00121081016 00121481040 00121481050 d57cde69-0eb9-180d-e053-2995a90a33aa 31e3da10-5a7b-4bc5-8a4f-3e786b64c13a |
Adverse event summaries are temporarily unavailable. Other product information remains available.